INTRODUCTION
HIV-related pediatric deaths in 2014 were impressively nearly 50% fewer than in 2004, largely because of reductions in new pediatric infections (58% decrease since 2000) through prevention of mother to child transmission (PMTCT) programs [1-3]. Nevertheless, HIV remains a leading cause of child deaths, especially among those more than 5 years old where the burden of children infected before good coverage of effective PMTCT is substan-
Globally, HIV is the 12th leading cause of child deaths and among the top five leading causes in high-prevalence countries [4 & ]. Optimizing survival of the 2.6 million children living with HIV therefore remains important [3] .
Survival of children in the absence of combination antiretroviral therapy
In sub-Saharan Africa, approximately half of perinatally infected and a quarter of infants infected through breastfeeding will die before their second birthday, compared with less than 5% infant mortality in HIV-exposed uninfected infants [5] [6] [7] .
Mortality in untreated perinatally infected infants was so high that in South Africa, it caused an increase in all-cause mortality at 2-3 months of age from 1997 to 2002 [8] . In the United States/Europe mortality in the absence of combination antiretroviral therapy (cART) was lower; 1-year mortality was 6.5-30% in 6-month-old infants [9, 10] .
Owing to survivor bias, mortality without cART decreases markedly in children surviving to 2 years. The Joint United Nations Programme on HIV/AIDS (UNAIDS) Spectrum model estimates that survival probability to age 20 years without cART increases with timing of infection from 9% (infected at birth) to 24% (infected through breastfeeding), although data to inform assumptions for children aged more than 2.5 years are limited [11 & ,12,13] . Annual mortality estimates without treatment in the United States/Europe ranged from 1.2-12.0% in 2 year olds to 0.2-2.1% in children aged 10 years; CD4 þ was a poorer predictor of mortality in younger children [10] . In resource-limited settings (RLS), mortality is higher for equivalent age and CD4 þ values, and CD4 þ is less discriminatory for predicting mortality than in well resourced countries; annual risk varied based on the percent of blood lymphocytes that are CD4 þ (CD4%) from 2.6-32.5% in 1-2 year olds to 0.6-23.0% in children at least 7 years old ( Fig. 1 ) [10, 14] . Viral load was a much weaker predictor of mortality than CD4 þ count/percentage [10] .
Impact of combination antiretroviral therapy on survival
Developed country cohorts of mainly older children, initially demonstrated the survival benefit of cART [15] . Subsequently, studies have examined whether there is a survival benefit of immediate vs. deferred therapy. The children with HIV early antiretroviral (CHER) randomized controlled trial (RCT) showed 75% mortality reduction by 40 weeks in infants aged less than 3 months who started immediate early limited cART (until first or second birthday) compared with deferring until
KEY POINTS
Good survival has been achieved during the cART era in all settings with up to 10-fold mortality reductions compared with before cART availability.
Immediate cART has been shown to improve survival compared with deferring until clinical or immunological progression in infants in the CHER RCT, and in children aged 5-10 years in causal modeling analyses of cohort data.
Since mortality risk remains high in the first few months after cART initiation in young children with severe disease, it is important to improve access to early diagnosis and cART before disease progression; nevertheless, mortality drops rapidly after the first 6 months on cART even for those who started with advanced disease, and longer term mortality risk is low in all settings.
Routine programs providing pediatric cART in RLS frequently report high loss to follow-up, which may include unascertained mortality and suboptimal retention on cART threatens potential good survival outcomes.
HIV-infected children continue to experience high comorbidity risk even when treated with cART with infections remaining the major cause of death; interventions shown to reduce infection risk and related mortality include cotrimoxazole prophylaxis, isoniazid preventive therapy, routine childhood and influenza immunization, and improving maternal survival. immunologic or clinical progression (defined as WHO 2006 cART initiation thresholds) [16] . However, a smaller RCT showed no mortality benefit of immediate cART at CD4 þ 15-24% vs. deferring until a CDC stage C event or CD4 þ less than 15% in older Thai children (median age 6.4 years) [17] . Notably, the overall event rate was low and few children were in the younger age groups where the benefit of immediate cART is likely to be highest [17] . Causal modeling analyses that adjust for timedependent confounding affected by prior treatment showed no mortality benefit of immediate cART in 1-5-year-old children, possibly because few children in routine care presented with CD4 þ count more than 750 cells/ml or CD4% more than 25% (WHO 2010 cART initiation threshold) and a high proportion was lost to follow-up (LTFU) with likely mortality underascertainment [18, 19] . For children 5-10 years old, causal modeling showed a small but significant mortality benefit of 0.4% (95% confidence interval: 0.02-0.6%) by 5 years of follow-up when starting cART immediately vs. deferring until CD4 þ less than 500 cells/ml ( Fig. 2) [20 && ]. ]. In the Antiretroviral Research for Watoto (ARROW) RCT of different monitoring strategies, 1-year mortality on cART ranged from 1.3 to 10.1% in children aged 4-15 years with CD4 þ at least 100 and less than 50 cells/ml, respectively [36] . Corresponding values for children 4 months to 3 years were 9.1% (CD4% < 5%) and 2.8% (CD4% > 10%) ( Fig. 3 ) [36] . Although mortality was high in the first 3 months of cART, it declined rapidly to less than 5% by 1 year for all age and CD4 þ strata [36] . Follow-up time (in months)
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CD4 + and WAZ thresholds for aART intiation for each strategy:
immediate ART <500 or -2 <350 or -2 <200 or -2 no ART Cumulative mortality FIGURE 2. Estimated mortality from enrolment into HIV care in children aged 5-10 years at enrolment with initial CD4 þ more than 500 cells/ml from Southern Africa, West Africa, and Europe comparing different cART initiation strategies as follows: immediate cART; cART at CD4 þ less than 500 or WAZ 2 or less; CD4 þ less than 350/WAZ 2 or less; CD4 þ less than 200/WAZ 2 or less; no cART. The mortality difference between immediate cART (solid green line) and deferring cART to CD4 þ more than 500 cells/ml or WAZ 2 or less is 0.4% (95% CI: 0.02-0.6%). Mortality is estimated from g-computation to adjust for time-dependent confounding affected by prior treatment of CD4 þ count, CD4 þ percentage, and WAZ. cART, combination antiretroviral therapy; CI, confidence interval; WAZ, weight-for-age z-score.
Routine cART programs in RLS suggest poorer and more variable survival than trials, partly because of lower retention and programmatic or adherencerelated challenges, including drug stockouts. Indeed, better survival in children with greater adherence to placebo in a cotrimoxazole prophylaxis trial suggests that good adherence may be a surrogate for overall better child care [37] . Mortality by 2 years or more on cART from routine programs in RLS ranges from 3.7 to 29% [38, 39] and rates vary from 1.3 to 6.0/100 child years [40, 41] . Children still initiate treatment with severe disease with mortality remaining higher in the first year ( Fig. 3 ) [42] . Young age and severe disease are consistently associated with higher mortality [28,31, [43] [44] [45] [46] . Prognostic models for RLS predict 1-year mortality on cART ranging from less than 2% (children 5-10 years, no severe disease, CD4% > 10%) to more than 45% (infants, severe disease, CD4% < 5%) [47 & ,48 ]. Nevertheless, nearly 60% of children in the prognostic model study cohort had characteristics predicting low (<5%) 1-year mortality [47 & ]. Importantly, there are concerns about survival on cART and interpreting outcomes of routine programs in RLS. First, routine cohorts frequently report high LTFU (>10%) with likely unascertained mortality [38, [49] [50] [51] . In Malawi, mortality was 11% among children traced from 3 weeks after a missed visit [52 & ]; using longer durations to define LTFU, mortality was nearly 40% among LTFU [38] . Second, many programs have high transfer rates, particularly in recent years with decentralization of cART programs [23,28,31,53-55,56 & ,57,58]. Although decentralization may contribute to better retention [54, 59] , limited ability to track outcomes after transfer hampers long-term survival assessment. Additionally, unrecorded transfers to another facility add to high LTFU rates with underestimation of survival at the program level [52 & ]. Third, some programs report worsening outcomes [39, 45, 54] ; from 2005 to 2008 in the Côte d'Ivoire, 1-year mortality and LTFU increased from 3 to 11% and 2 to 23%, respectively [45] . In rural Mozambique, mortality and LTFU were 16-24% and 25-70%, respectively with substantial heterogeneity between districts [39] . Infant survival requires early infant diagnosis (EID) with rapid cART initiation. In 2014, only 50% of HIV-exposed infants were tested by age 2 months; only a third of those diagnosed started cART promptly [66] [67] [68] . At best, most infants initiate treatment between 12 and 14 weeks, after the infant mortality peak [8, 69] . Innovative approaches (pointof-care assays; adding birth EID) may accelerate diagnosis and cART initiation, but further implementation research is needed [ 
Tuberculosis
In 2015, global estimates showed that up to 30% of HIV-infected child deaths may be tuberculosisrelated [95] . HIV-infected children are more than twice as likely to die from tuberculosis compared with HIV-uninfected children [96] [97] [98] ; within pediatric HIV cohorts, tuberculosis increases mortality risk 2-4 times [99, 100] . Infants are at the highest risk with nearly 30% mortality with bacteriologically confirmed tuberculosis [101] . Although cART reduces tuberculosis-related mortality substantially [99, 102] , delays in cART initiation remain challenging [100, 103] . Unlike in adults [104, 105] , there are no RCTs on the optimal timing of cART initiation in tuberculosis coinfected children. Observational studies showed better survival with starting cART within 2 months (or less) of tuberculosis therapy compared with later [106] [107] [108] , but it is unclear whether early cART improves survival in coinfected children without severe immunocompromise.
Treatment outcomes for children with drugresistant tuberculosis vary widely. A South African study of drug-resistant tuberculosis (55% of children HIV-infected) found 20% overall mortality [109] , whereas a systematic review found mortality was twice as high in HIV-infected compared with uninfected children (11.5 vs. 6%) [110 && ].
Malignancy
Cancer is at least 5-10 times more common in HIVinfected compared with uninfected children [87, 91,111 && ,112,113] . In the cART era, AIDSdefining cancers (ADCs) have reduced dramatically, but non-ADC rates remain unchanged or increased [87, 91, 114] . Treatment outcomes are worse in HIVinfected vs. HIV-uninfected children [111 && ]. In South Africa, more than 80% of HIV-infected children with cancer presented with advanced disease; only a third survived. Survival was higher (57.8%) if treated with cART and chemotherapy [115] . In Uganda, half of HIV-infected children with cancer died or were LTFU; mortality was at least three-fold higher than the clinic crude mortality rate (33 vs. 5-10%) [116] . The increasing rates of some non-ADCs in the cART era are likely because of increased life expectancy allowing development of these cancers; however, the impact of long-term cART has been debated. With vertically infected children surviving into adulthood there is growing concern about malignancy risk and associated mortality.
Interventions other than antiretroviral therapy to improve survival in HIV-infected children
Cotrimoxazole Use of cotrimoxazole nearly halved all-cause mortality in cART-naïve Zambian children despite high levels of bacterial resistance [117, 118] . The ARROW trial found fewer hospitalizations when continuing cotrimoxazole in Ugandan/Zimbabwean children after 2 years of cART; hence, WHO recommends continuing prophylaxis until adulthood if prevalence of bacterial infections and malaria is high [119,120 && ]. Cotrimoxazole appears protective against incident tuberculosis in HIVinfected adults and possibly children [89 && ,121] and reduces mortality and morbidity in people with HIV/tuberculosis [122, 123] . Adding cotrimoxazole to antituberculosis treatment has been successfully implemented in high tuberculosis burden countries with 87% coverage in coinfected patients [95] .
Evidence of survival benefit of isoniazid preventive treatment (IPT) in HIV-infected children is conflicting. IPT halved all-cause mortality in an RCT including mostly cART-naïve children [124] ; a subsequent cohort study demonstrated additional benefit of IPT on tuberculosis incidence in children on cART [125] . Contrastingly, an RCT in infants showed no mortality or tuberculosis prevention benefit of pre-exposure IPT [126] ; however, infants were screened for tuberculosis exposure at every visit, with prompt postexposure IPT. Although this approach is unlikely to be feasible in routine care where uptake of post-exposure IPT has been shown to be very low [127, 128] , pre-exposure IPT for children in HIV clinics can have high uptake and treatment completion [129] . Although WHO has recommended pre-exposure IPT since 2004, coverage remains disappointingly low [95] . Barriers to IPT implementation include exaggerated fear of resistance development [130 & ], unavailability of single entity isoniazid formulations in RLS, and concerns about increased pill burden affecting cART adherence [131 & ]. A scored fixed-dose combination of isoniazid, vitamin B6, and cotrimoxazole was highly acceptable to adults and children more than 5 years in the Reduction of EArly mortaLITY in HIVinfected Adults and Children Starting Antiretroviral Therapy (REALITY) trial [132] and could help overcome universal IPT implementation barriers; a half-strength scored dispersible tablet is needed for younger children.
Routine immunization
Since common childhood infections remain the leading causes of death in HIV-infected children, routine childhood immunizations may improve survival [94] . ]. Further, PCV appeared protective against tuberculosis [134] . The high prevalence of rotavirus gastroenteritis in HIV-infected infants in RLS indicates a potential survival benefit of vaccination [135, 136] . Rotavirus vaccine efficacy is lower in high-mortality countries but disease burden is higher, hence the absolute benefit is large [137] . A package of preventive strategies addressing common comorbidities should be considered to optimize survival.
Maternal health, socioeconomic status, and treatment of OI in adults
Several studies show links between maternal and infant survival -maternal HIV/AIDS or tuberculosis-related death reduce child survival [138] [139] [140] . Maternal cART protected against under-five mortality; death rates in children of HIV-infected mothers were reduced to levels of children of HIVuninfected mothers [141] . Maternal health is therefore important and 'Option Bþ' (lifelong cART for pregnant/breastfeeding women) offers key child survival benefit.
CONCLUSION
Pediatric survival has improved substantially with cART; with the additional success of PMTCT programs in preventing new infant infections, focus can start to shift from averting deaths to optimizing health for adolescence and adulthood. Nevertheless, there remain substantial survival gains to be made especially in RLS by strengthening health systems and improving models of decentralized HIV care to ensure access to diagnosis and early cART at all levels of the health system, continuous drug supplies, better adherence and retention, prophylaxis and treatment for comorbidities, as well as promoting maternal survival including maternal cART. national Epidemiologic Databases to Evaluate AIDS Southern Africa) and R01HD075156 (Closing the gaps in PMTCT program coverage, early infant diagnosis and treatment).
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There are no conflicts of interest. ). An analysis of cohort data from West and Southern Africa as well as Europe examining mortality and growth differences for different treatment initiation strategies in children 5-15 years of age using g-computation to adjust for time-dependent confounding affected by prior treatment. It shows lower mortality and better growth with immediate cART vs deferring to CD4 þ less than 500 in children 5-10 years of age, but differences are less clear for adolescents. The long-term outcomes of the CHER trial are reported in this study, which shows low mortality overall for nearly 5 years of follow-up for infants initiating cART at less than 3 months of age before the onset of disease progression. Children who initiated treatment early and subsequently had planned treatment interruption after either 40 weeks or 96 weeks on cART had lower mortality and severe disease events and spent less total time on cART compared with those for who initial therapy was deferred until clinical or immunological progression. Collins IJ, Cairns J, Ngo-Giang-Huong N, et al. Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in Thailand. PLoS One 2014; 9:e91004. The cost-effectiveness analysis compared EID using with immediate ART or EID with deferred ART based on immune/clinical criteria with later clinical/serologybased diagnosis and deferred ART. EID with immediate ART was more cost effective than EID with deferred ART with a cost-effectiveness ratio of USD2615/ life year gained compared with later clinical/serology-based diagnosis and deferred ART and would lead to major survival benefits. The retrospective study showed that influenza epidemics were followed by increase in the hospitalizations for confirmed pulmonary tuberculosis and invasive pneumococcal disease, particularly in HIV-infected children. The authors discuss possible interactions between the host and these infectious agents and suggest that vaccination against influenza virus or pneumococcal disease may alter the epidemiology of hospitalizations in children in the similar settings.
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